AGED Diagnostics

Cover Block

Public sources

Field	Value
Name	AGED Diagnostics
Tagline	Developing noninvasive blood tests for early detection and staging of liver diseases like MASH and fibrosis. [TEDCO, August 2025]
Headquarters	Rockville/Bethesda area [TEDCO, August 2025]
Founded	2018 [Crunchbase]
Stage	Seed [TEDCO, August 2025]
Business Model	B2B
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Solo Founder, Rachel Zayas [F6S]
Funding Label	Seed
Total Disclosed Funding	Approximately $250,000, based on TEDCO's disclosed Pre-Seed Builder Fund investment [TEDCO, August 2025]

Links

Public sources

• Website: https://www.ageddiagnostics.com/

Executive Summary

PUBLIC AGED Diagnostics is developing noninvasive blood tests for early detection and staging of liver disease, with a stated focus on MASH and fibrosis, and it merits attention now because TEDCO publicly backed the company in August 2025 while local reporting in May 2026 showed the program still advancing through preclinical and validation work [TEDCO, August 2025] [DC News Now, May 2026]. Founded in 2018, the company is framed in public materials as an effort to address what management and affiliated profiles describe as a diagnostic gap between invasive liver biopsy and less precise imaging or blood-based approaches, though that framing remains largely company-sourced [Crunchbase] [TEDCO, August 2025] [AGED Diagnostics].

The core product is a blood test intended to diagnose MASH and stage liver fibrosis across the disease spectrum, with the technical approach described across public profiles as targeted sequencing and biomarker analysis; a Veeva clinical-trial entry also points to whole genome bisulfite sequencing work in tissue and plasma biomarker discovery [Plug and Play Tech Center] [Veeva CTV] [TEDCO, August 2025]. Reported performance signals are directionally interesting but still early: Plug and Play cites pilot accuracy of 90 to 99 percent, while an F4 profile says AGED completed a 300-patient verification study with more than 95 percent accuracy, neither of which appears independently validated in peer-reviewed or regulatory materials from the sources provided [Plug and Play Tech Center] [F4].

Public materials identify Rachel Zayas as founder and CEO, with profiles describing her as a geneticist, a two-time founder, and a former MIT researcher with a master's degree in biotechnology and business; those credentials are relevant to assay development, even if the broader operating bench is only lightly documented in public sources [F6S] [LinkedIn, retrieved 2026]. The company is presented variously as a solo-founder business and as a broader team of geneticists and hepatologists, but the named public roster remains thin, which makes team build-out an item to monitor rather than a settled strength [MTEC] [LinkedIn, retrieved 2026].

On financing, the only clearly confirmed round in the provided materials is TEDCO's $250,000 Pre-Seed Builder Fund investment in August 2025, and the company is categorized here as seed-stage with a B2B model [TEDCO, August 2025]. Over the next 12 to 18 months, the public milestones that matter most are whether AGED can convert reported verification results into independently legible clinical-validation data, show progress toward the cited 15 to 25 site blinded study, and clarify the eventual commercial path into provider, lab, or biopharma workflows [F4] [DC News Now, May 2026].

Company-stated, unverified -- This section relies materially on company, accelerator, and affiliated profile claims, with limited independent public corroboration beyond TEDCO's funding announcement and DC News Now's coverage.

Taxonomy Snapshot

Axis	Value
Stage	Seed
Business Model	B2B
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding	$250,000 disclosed pre-seed investment from TEDCO Pre-Seed Builder Fund [TEDCO, August 2025]

How the Company Got Here

PUBLIC

AGED Diagnostics presents as an early-stage biotech company built around a narrow but clinically consequential problem: detecting and staging liver disease with a blood draw rather than an invasive biopsy. Public company materials describe the business as developing noninvasive blood tests for early liver-disease detection, particularly MASH and liver fibrosis, while Crunchbase lists the company as founded in 2018 and based in the Bethesda area [AGED Diagnostics] [Crunchbase].

The public record is still thin, so chronology matters more than narrative flourish here. Crunchbase places the company’s founding in 2018 [Crunchbase]. The company website frames the current focus as improving identification of patients earlier across the liver-disease spectrum through blood-based diagnostics rather than existing biopsy, imaging, or conventional blood-test approaches [AGED Diagnostics]. By August 2025, TEDCO publicly announced a $250,000 Pre-Seed Builder Fund investment into AGED Diagnostics for research and development tied to early liver-disease detection, which is the clearest externally dated milestone in the company’s disclosed history [TEDCO, August 2025].

A second recent milestone is visibility in Maryland’s startup and health innovation channels rather than broad national coverage. DC News Now reported in May 2026 that AGED Diagnostics was developing a blood test for liver disease detection and had received a Montgomery County Technology Innovation Fund grant, although the amount and timing of that grant were not detailed in the cited coverage [DC News Now, May 2026]. Public materials also show the company maintaining an active website and startup-platform presence, but they do not clearly disclose a legal entity name beyond the operating brand [AGED Diagnostics] [Crunchbase].

Lightly corroborated -- Company identity, founding year, location, and product focus are supported by Crunchbase and the company website, while later milestones rely partly on single-source public reporting.

Product and Technology

MIXED Product scope and clinical intent

The technical claim is straightforward, and still early. AGED Diagnostics says it is developing noninvasive blood tests for early detection and staging of liver disease, with a particular focus on MASH and liver fibrosis, and multiple public descriptions frame the product as an attempt to reduce reliance on liver biopsy and improve on imaging-led diagnosis through targeted sequencing and biomarker analysis [TEDCO, August 2025] [Plug and Play Tech Center] [AGED Diagnostics].

Public materials describe the assay as a blood-based diagnostic intended to distinguish disease states across the spectrum rather than merely flag liver injury in general. Plug and Play says pilot work showed 90 to 99 percent accuracy in differentiating benign and advanced MASH using targeted sequencing and biomarker analysis, while an F4 company profile says AGED completed a 300-patient verification study with more than 95 percent accuracy differentiating simple steatosis from NASH and early from advanced fibrosis [Plug and Play Tech Center] [F4]. Those performance figures are company-linked and not independently validated in a peer-reviewed source in the materials provided, so they are best read as directional evidence of technical ambition rather than settled clinical proof.

A more specific window into the underlying science comes from a public clinical-trial listing that says the company conducts whole genome bisulfite sequencing in patient liver tissue and plasma to identify biomarkers that can discriminate between steatosis and NASH, including fibrosis staging across mild, significant, and advanced disease [Veeva CTV, retrieved 2026]. That description is consistent with the broader product narrative in TEDCO and Plug and Play materials, but there is no verified public demo, regulatory clearance, or commercial deployment detail in the record here, and no defensible basis to infer a broader software or diagnostics infrastructure from the single surfaced Indeed listing [Indeed, retrieved 2026].

Company-stated, unverified -- This section relies primarily on company descriptions and ecosystem profiles, with no independent peer-reviewed validation or public commercial deployment evidence in the cited record.

Where the Demand Sits

PUBLIC The market matters now because liver disease is common, diagnosis is still constrained by invasive or imperfect tools, and public market data shows a large diagnostics spend even before narrower MASH-specific adoption is fully proven [Yahoo Finance, retrieved 2026] [TEDCO, August 2025] [DC News Now, May 2026].

Public market sizing for AGED Diagnostics is thin, and that matters for how much weight investors should put on headline opportunity. The only third-party market figure captured in the record is a Yahoo Finance-cited estimate that the global liver disease diagnostics market was $32.2 billion in 2025 and is projected to reach $47.6 billion by 2032, implying a 5.7% CAGR from 2025 to 2032 [Yahoo Finance, retrieved 2026]. By contrast, AGED-linked materials cite a global liver disease burden of about 2 billion patients, about 100 million patients in the U.S., and a 25 million patient target market, but those figures come through startup-profile materials rather than an independently established epidemiology or market-research source, so they are better read as directional framing than as a bankable TAM build [47pitches] [AGED Diagnostics, retrieved 2026].

Market segment	Figure	Scope	Source quality
Liver disease diagnostics market	$32.2B	Global, 2025	Third-party market report via publisher [Yahoo Finance, retrieved 2026]
Liver disease diagnostics market	$47.6B	Global, 2032 projection	Third-party market report via publisher [Yahoo Finance, retrieved 2026]
CAGR	5.7%	2025 to 2032	Third-party market report via publisher [Yahoo Finance, retrieved 2026]
Target market	25M patients	Company target market framing	Startup-profile source [47pitches]

The table points to a useful distinction. The broad diagnostics market appears large enough to support multiple winners, but the narrower addressable segment for a MASH and fibrosis blood test still needs sharper public definition before market-share assumptions become credible.

Demand drivers are clearer than the market map. TEDCO describes AGED as building for early liver-disease detection and intervention, with the explicit goal of reducing reliance on liver biopsy and improving on imaging-based diagnosis through targeted sequencing and biomarker analysis [TEDCO, August 2025]. DC News Now similarly frames the unmet need around earlier, noninvasive detection for MASH and fibrosis, while the company site says fatty liver disease affects 1 in 3 Americans, a prevalence claim that, while company-sourced, is directionally consistent with why providers and payers are paying closer attention to screening and staging workflows [DC News Now, May 2026] [AGED Diagnostics, retrieved 2026]. In practical terms, the tailwind here is not only disease prevalence. It is the clinical and operational friction created when the reference standard is biopsy and the alternatives do not reliably identify patients across the full disease spectrum, according to company materials [AGED Diagnostics, retrieved 2026] [MTEC, retrieved 2026].

The relevant adjacent markets are broader than liver diagnostics alone. A blood-based test for MASH and fibrosis sits at the intersection of hepatology diagnostics, molecular diagnostics, routine clinical lab testing, and drug-development enablement for liver disease programs, although the last category remains inferential because no public biopharma partnerships are confirmed in the record [Plug and Play Tech Center, Unknown] [TEDCO, August 2025]. Substitute pathways remain entrenched, notably liver biopsy, imaging, and existing blood tests, which the company itself identifies as the incumbent standard set it is trying to improve upon [AGED Diagnostics, retrieved 2026]. That is a favorable setup if performance holds in validation, but it also means adoption will likely depend on evidence thresholds that are higher than for a wellness or screening product.

Regulatory and macro forces cut both ways. On the positive side, the combination of high disease burden, interest in earlier intervention, and local public support such as TEDCO funding and a Montgomery County Technology Innovation Fund grant suggests that noninvasive liver diagnostics fit current public-health and regional innovation priorities [TEDCO, August 2025] [DC News Now, May 2026]. The constraint is that the public record here does not yet show named reimbursement wins, regulatory clearances, or independently corroborated multisite validation progress, so the market opportunity is best understood as structurally real but commercially unproven at this stage [F4] [DC News Now, May 2026].

Single unverified source -- This section relies on one third-party market-sizing source, plus company and startup-profile materials for prevalence and target-market framing [Yahoo Finance, retrieved 2026] [AGED Diagnostics, retrieved 2026] [47pitches].

Competitive Landscape

MIXED AGED Diagnostics is competing less against a single startup peer set than against the current liver-disease diagnostic workflow itself, where biopsy, imaging, and existing blood-based assessments remain the practical default in care pathways according to the company and its backers [TEDCO, August 2025] [AGED Diagnostics] [MTEC].

The public record is thin on named direct startup competitors, which matters because it limits any precise share-of-voice or feature-by-feature mapping. What can be said from public sources is narrower and still useful: AGED is positioning its product as a noninvasive blood test for MASH diagnosis and liver fibrosis staging, with the stated aim of improving on biopsy and imaging through targeted sequencing and biomarker analysis [TEDCO, August 2025] [Plug and Play Tech Center] [AGED Diagnostics]. In practice, that places the company in a contest across three layers: incumbent clinical methods such as liver biopsy and imaging, existing blood-based diagnostics as a substitute class, and a broader group of molecular-diagnostics developers pursuing earlier and more granular detection in chronic disease [AGED Diagnostics] [MTEC] [Veeva CTV].

That framing cuts both ways. On one hand, the company is pursuing a real pain point. Multiple public descriptions of the product emphasize earlier detection and reduced dependence on invasive procedures, which is a credible clinical and commercial wedge if validated in blinded, multi-site settings [TEDCO, August 2025] [DC News Now, May 2026] [F4]. On the other hand, the absence of publicly verified named customers, lab partnerships, or reimbursement infrastructure means AGED is still competing from the development stage rather than from an owned distribution channel [Plug and Play Tech Center] [F4].

Where AGED appears to have an edge today is in the specificity of its technical claim, not in scale. The company and affiliated profiles describe a sequencing and biomarker approach intended to distinguish steatosis from NASH or MASH and to stage fibrosis across the disease spectrum, with one company profile citing a 300-patient verification study and reported accuracy above 95%, and Plug and Play citing pilot results in the 90 to 99 percent range [F4] [Plug and Play Tech Center]. If those figures hold up under blinded validation, the asset is potentially durable because disease-stage discrimination is more valuable than a binary screen. Still, the durability is perishable until independently replicated. At present, the evidence is largely company-linked or ecosystem-linked rather than third-party clinical publication, and there is no public indication yet of regulatory clearance, commercial launch, or payer adoption [DC News Now, May 2026] [AGED Diagnostics] [Veeva CTV].

The company is most exposed where incumbents already control workflow. Biopsy and imaging are imperfect, but they are embedded in specialist practice and care pathways today, and AGED's public materials themselves are effectively an argument against those incumbents' limitations rather than proof of displacement at the point of care [AGED Diagnostics] [TEDCO, August 2025]. The other exposure is capital and proof depth. TEDCO's disclosed $250,000 pre-seed investment is useful validation at the state-backed ecosystem level, but it is modest relative to the evidentiary burden of diagnostics development, especially if the company needs multi-site validation, laboratory integration, and eventual reimbursement workstreams [TEDCO, August 2025]. With no named direct competitor confirmed in the source set, the sharper competitive risk is not one startup outflanking AGED on branding, but a better-capitalized diagnostics developer or incumbent test provider reaching clinical acceptance first.

The most plausible 18-month scenario is a sorting event around evidence quality rather than pure product messaging. Winner if X: AGED Diagnostics, if it can convert the reported verification results into a blinded multi-site validation data package that confirms accuracy claims in real-world cohorts and gives providers a reason to trial a blood-based alternative before biopsy escalation [F4] [DC News Now, May 2026]. Loser if Y: AGED Diagnostics, if validation takes longer than expected or fails to reproduce early performance, because in that case the existing diagnostic stack, meaning biopsy, imaging, and established blood-test substitutes as a category, keeps the clinical default by inertia as much as by superiority [AGED Diagnostics] [TEDCO, August 2025].

Opportunity

PUBLIC

The prize here is unusually large for a seed-stage diagnostics company: if AGED Diagnostics can prove that a blood draw can reliably detect and stage MASH and liver fibrosis earlier than current workflows, it is aiming at a disease area measured in tens of millions of patients in the US alone and a diagnostics market that one industry report estimates at $32.2 billion in 2025, rising to $47.6 billion by 2032 [AGED Diagnostics, Unknown] [Yahoo Finance].

The headline opportunity is not simply to sell another lab test. It is to become a clinically trusted front door for liver-disease stratification, particularly in the gap between broad-risk screening and invasive biopsy. That outcome remains conditional, but the public evidence does show the rough ingredients needed for it to be reachable rather than purely aspirational: the company is developing a noninvasive blood test for MASH and fibrosis staging [TEDCO, August 2025] [Plug and Play Tech Center], it has publicly described biomarker discovery work using whole genome bisulfite sequencing across liver tissue and plasma [Veeva CTV], and third-party profiles attribute to AGED a completed 300-patient verification study with reported accuracy above 95% on certain differentiation tasks [F4]. None of that yet establishes clinical adoption, reimbursement, or regulatory clearance. It does, however, define a coherent wedge in a large unmet-need category where earlier and less invasive diagnosis is a commercially meaningful claim if validated [DC News Now, May 2026] [TEDCO, August 2025].

The upside cases split into a few distinct paths, each dependent on different proof points.

Scenario	What happens	Catalyst	Why it's plausible
Specialty-care wedge	AGED becomes a preferred blood-based triage and staging tool for hepatology and gastroenterology workflows before biopsy decisions	Successful blinded multi-site clinical validation after the reported verification study [F4]	The company is already positioning around noninvasive detection and staging, and public materials describe completed verification work plus plans for broader validation [TEDCO, August 2025] [F4]
Biopharma-enablement path	AGED is used to identify and stratify patients for liver-disease drug development programs	Demonstration that the assay can distinguish disease stages across the fibrosis spectrum in clinical-study settings [Plug and Play Tech Center] [Veeva CTV]	Public descriptions of the technology emphasize staging across the disease spectrum, which is directly relevant to trial enrollment and response monitoring even before broad routine-care use [Plug and Play Tech Center] [Veeva CTV]
Platform expansion beyond one assay	AGED turns its methylation and biomarker discovery workflow into a broader liver-diagnostics platform with multiple indications or repeated-use products	Validation of the first MASH and fibrosis test, followed by additional biomarker applications derived from the same discovery engine [Veeva CTV] [AGED Diagnostics, Unknown]	The company is not framed publicly as a single-analyte test developer. Its materials point to a biomarker-discovery approach using tissue and plasma, which can support follow-on assays if the first clinical use case lands [Veeva CTV] [AGED Diagnostics, Unknown]

The compounding mechanism, if one appears, would likely come from clinical data and workflow fit rather than a classic consumer network effect. A diagnostics company in this position can improve distribution and defensibility as each validation cohort, practice adoption, and research use case adds evidence on performance across disease stages. AGED's public materials already point in that direction: the company says current tools miss patients early across the disease spectrum [AGED Diagnostics, Unknown], while third-party profiles describe both pilot work showing 90 to 99 percent accuracy in differentiating benign and advanced MASH and a larger 300-patient verification study [Plug and Play Tech Center] [F4]. If those signals hold up under blinded, multi-site validation, the same evidence base can support physician trust, lab partnerships, and possible use in biopharma studies. In diagnostics, that is the flywheel that matters: more validated samples can improve credibility, and credibility can open the next channel.

The size of the win can be framed, cautiously, through market capture rather than by forcing an unsupported valuation comparable. Yahoo Finance cites a liver disease diagnostics market of $32.2 billion in 2025, projected to reach $47.6 billion by 2032 [Yahoo Finance]. If AGED ultimately built a clinically established position worth even 1 percent of the projected 2032 market, that would imply roughly $476 million in annual market value captured at the category level (scenario, not a forecast) [Yahoo Finance]. A narrower framing also matters: the company has described a target market of 25 million patients, though that figure comes from a company-adjacent source and should be treated cautiously [47pitches]. For investors, the key point is that this is one of the few seed-stage healthcare bets where a successful first product could plausibly lead to a much broader position in screening, staging, and therapy-selection workflows, rather than ending at a single niche assay.

Company-stated, unverified -- This section relies materially on company-linked and single-source claims about test performance, market size, and development status, with limited independent public corroboration beyond TEDCO and local news coverage.

Sources

Public sources

1. [TEDCO, August 2025] TEDCO Invests in AGED Diagnostics | https://www.tedcomd.com/news-events/press-releases/2025/tedco-invests-aged-diagnostics

2. [Crunchbase] AGED Diagnostics - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/age-diagnostics

3. [F6S] Rachel Zayas | https://www.f6s.com/member/rachelzayas

4. [DC News Now, May 2026] AGED Diagnostics develops blood test for liver disease detection | https://www.dcnewsnow.com/news/local-news/maryland/moco-minute-maryland/aged-diagnostics-develops-blood-test-for-liver-disease-detection/

5. [AGED Diagnostics] Home | AGED Diagnostics | https://www.ageddiagnostics.com/

6. [Plug and Play Tech Center] AGED Diagnostics | https://www.plugandplaytechcenter.com/startup/ageddiagnostics-com

7. [Veeva CTV] Clinical trial listing referencing AGED Diagnostics biomarker discovery work | https://ctv.veeva.com/

8. [F4] AGED Diagnostics | Healthcare & Digital Health | F4 | https://f4.fund/startups/ageddiagnostics

9. [LinkedIn, retrieved 2026] River Jiang - University of California, San Francisco | LinkedIn | https://www.linkedin.com/in/riverjiang/

10. [MTEC, retrieved 2026] AGED Diagnostics company profile | https://mtec-sc.org/

11. [Indeed, retrieved 2026] Aged Diagnostics Jobs, Employment in Bethesda, MD | Indeed | https://www.indeed.com/q-aged-diagnostics-l-bethesda,-md-jobs.html

12. [Yahoo Finance, retrieved 2026] Liver Disease Diagnostics Market projected to reach US$47.6 Billion by 2032 | https://finance.yahoo.com/

13. [47pitches] AGED Diagnostics profile | https://47pitches.com/